RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Standard BioTools Stock

Standard BioTools P/S 2024

Standard BioTools P/S

0.97

Ticker

LAB

ISIN

US34385P1084

WKN

A0RADJ

As of Aug 10, 2024, Standard BioTools's P/S ratio stood at 0.97, a -43.93% change from the 1.73 P/S ratio recorded in the previous year.

The Standard BioTools P/S history

Standard BioTools Aktienanalyse

What does Standard BioTools do?

Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Standard BioTools's P/S Ratio

Standard BioTools's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Standard BioTools's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Standard BioTools's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Standard BioTools’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Standard BioTools stock

What is the price-to-earnings ratio of Standard BioTools?

The price-earnings ratio of Standard BioTools is currently 0.97.

How has the price-earnings ratio of Standard BioTools changed compared to last year?

The price-to-earnings ratio of Standard BioTools has increased by -43.93% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Standard BioTools high compared to other companies?

Yes, the price-to-earnings ratio of Standard BioTools is high compared to other companies.

How does an increase in the price-earnings ratio of Standard BioTools affect the company?

An increase in the price-earnings ratio of Standard BioTools would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Standard BioTools affect the company?

A decrease in the price-earnings ratio of Standard BioTools would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Standard BioTools?

Some factors that influence the price-earnings ratio of Standard BioTools are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Standard BioTools pay?

Over the past 12 months, Standard BioTools paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Standard BioTools is expected to pay a dividend of 0 USD.

What is the dividend yield of Standard BioTools?

The current dividend yield of Standard BioTools is .

When does Standard BioTools pay dividends?

Standard BioTools pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Standard BioTools?

Standard BioTools paid dividends every year for the past 0 years.

What is the dividend of Standard BioTools?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Standard BioTools located?

Standard BioTools is assigned to the 'Health' sector.

Wann musste ich die Aktien von Standard BioTools kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Standard BioTools from 8/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/10/2024.

When did Standard BioTools pay the last dividend?

The last dividend was paid out on 8/10/2024.

What was the dividend of Standard BioTools in the year 2023?

In the year 2023, Standard BioTools distributed 0 USD as dividends.

In which currency does Standard BioTools pay out the dividend?

The dividends of Standard BioTools are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Standard BioTools stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Standard BioTools

Our stock analysis for Standard BioTools Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Standard BioTools Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.